The NIH announced that it is launching a phase 2 human challenge trial of AV-1, an investigational monoclonal antibody to ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback